Clinical Trials Browser

Phase 1 × NETWORK × VTX-2337 × Clear all

NCT01294293 2014-12-25

TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer

Phase 1 Completed

Brenner Tumor, Fallopian Tube Neoplasms, Ovarian Neoplasms